Adjuvant mRNA-4157 Plus Pembrolizumab Improves RFS in Resected High-Risk Melanoma

mRNA-4157 in combination with pembrolizumab improved recurrence-free survival compared with pembrolizumab alone when used as an adjuvant treatment in patients with resected high-risk melanoma, regardless of tumor mutational burden.

Related Keywords

New York ,United States ,Massachusetts ,Celldex Incyte ,Bristol Myers Squibb ,Ryan Sullivan ,Jeffreys Weber ,Serono ,Grossman School Of Medicine ,Astrazeneca ,Pfizer ,Melanoma Program At Massachusetts ,Novartis ,Genentech ,Harvard Medical School ,Langone Perlmutter Cancer Center ,Cancer Center ,Perlmutter Cancer Center ,Isaac Perlmutter Professor ,Cancer Care ,Melanoma Program ,Massachusetts General Cancer Center ,Instill Bio ,Mrna 4157 ,Pembrolizumab ,Vaccine ,High Risk Melanoma ,Melanoma ,Skin Cancer ,Keynote 942 Trial ,Recurrence Free Survival ,Rfs ,Taacr ,Aacr Annual Meeting ,Mrna 4157 P201 ,Mrna ,D ,Phd ,Nyu Langone ,Massachussetts General Cancer Center ,Giants Of Cancer Care ,